Current systemic therapy for metastatic melanoma - PubMed

Review

Current systemic therapy for metastatic melanoma

Sanjiv S Agarwala. Expert Rev Anticancer Ther. 2009 May.

Abstract

Metastatic melanoma remains a lethal disease with a long-term remission rate of less than 10%. Despite many years of research, there has not been a new drug approved in this disease in over two decades. Single-agent chemotherapy is palliative in some patients and there is no advantage of combination chemotherapy or chemo-immunotherapy in randomized trials. High-dose bolus IL-2 produces some long-term remissions and is available for highly selected individuals at selected centers in the USA but is impractical for most patients. Research is ongoing in exploring novel immunotherapeutic and targeted approaches. The status of recently completed and ongoing trials is discussed in this review.

Similar articles

• Interleukin-2 for the treatment of melanoma.

  Tarhini AA, Agarwala SS. Tarhini AA, et al. Curr Opin Investig Drugs. 2005 Dec;6(12):1234-9. Curr Opin Investig Drugs. 2005. PMID: 16370388 Review.

• Management of metastatic melanoma 2005.

  O'Day S, Boasberg P. O'Day S, et al. Surg Oncol Clin N Am. 2006 Apr;15(2):419-37. doi: 10.1016/j.soc.2005.12.002. Surg Oncol Clin N Am. 2006. PMID: 16632224 Review.

• Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

  Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S. Minor DR, et al. Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23. Oncologist. 2009. PMID: 19776094

• Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.

  Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Garbe C, et al. Melanoma Res. 2008 Apr;18(2):152-60. doi: 10.1097/CMR.0b013e3282f702bf. Melanoma Res. 2008. PMID: 18337653

• Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.

  Kwan KG, Kapoor A. Kwan KG, et al. Curr Opin Support Palliat Care. 2009 Sep;3(3):157-65. doi: 10.1097/SPC.0b013e32832e466b. Curr Opin Support Palliat Care. 2009. PMID: 19528804 Review.

Cited by

• A new understanding in the epidemiology of melanoma.

  Erdei E, Torres SM. Erdei E, et al. Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23. doi: 10.1586/era.10.170. Expert Rev Anticancer Ther. 2010. PMID: 21080806 Free PMC article. Review.

• Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.

  Tarhini A. Tarhini A. Scientifica (Cairo). 2013;2013:857519. doi: 10.1155/2013/857519. Epub 2013 Apr 17. Scientifica (Cairo). 2013. PMID: 24278787 Free PMC article. Review.

• Targeting the RAS pathway in melanoma.

  Ji Z, Flaherty KT, Tsao H. Ji Z, et al. Trends Mol Med. 2012 Jan;18(1):27-35. doi: 10.1016/j.molmed.2011.08.001. Epub 2011 Sep 30. Trends Mol Med. 2012. PMID: 21962474 Free PMC article. Review.

• Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

  Kovács P, Pánczél G, Borbola K, Juhász G, Liszkay G. Kovács P, et al. Pathol Oncol Res. 2014 Oct;20(4):939-44. doi: 10.1007/s12253-014-9777-7. Epub 2014 Apr 27. Pathol Oncol Res. 2014. PMID: 24771289

• Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.

  Lu B, Dai WF, Croxford R, Isaranuwatchai W, Beca J, Menjak IB, Petrella TM, Mittmann N, Earle CC, Gavura S, Mercer RE, Hanna TP, Chan KKW. Lu B, et al. Cancer Med. 2023 May;12(10):11451-11461. doi: 10.1002/cam4.5862. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999965 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information